Accéder au contenu
Merck

Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France.

Antimicrobial agents and chemotherapy (2010-04-14)
A Morvan, C Moubareck, A Leclercq, M Hervé-Bazin, S Bremont, M Lecuit, P Courvalin, A Le Monnier
RÉSUMÉ

Susceptibility to antibiotics of 4,816 clinical L. monocytogenes strains isolated since 1926 was studied, and the temporal evolution of susceptibility to antibiotics was analyzed through several decades. The mechanisms of resistance in each resistant strain were studied. The prevalence of resistant strains was estimated at 1.27% among isolates from humans. Resistance to tetracyclines+ and fluoroquinolones was more common and has recently emerged. Although acquired resistance in clinical L. monocytogenes did not implicate clinically relevant antibiotics, the possibility of resistance gene transfers, the description of the first clinical isolate with high-level resistance to trimethoprim, and the recent increase in penicillin MICs up to 2 microg/ml reinforce the need for microbiological surveillance.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Triméthoprime, ≥98.5%
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Sigma-Aldrich
Triméthoprime, ≥99.0% (HPLC)
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Supelco
Triméthoprime, VETRANAL®, analytical standard
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.